229 related articles for article (PubMed ID: 23370991)
1. Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis.
Gentile A; Rossi S; Studer V; Motta C; De Chiara V; Musella A; Sepman H; Fresegna D; Musumeci G; Grasselli G; Haji N; Weiss S; Hayardeny L; Mandolesi G; Centonze D
J Neuroimmune Pharmacol; 2013 Jun; 8(3):651-63. PubMed ID: 23370991
[TBL] [Abstract][Full Text] [Related]
2. Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Moore S; Khalaj AJ; Patel R; Yoon J; Ichwan D; Hayardeny L; Tiwari-Woodruff SK
J Neurosci Res; 2014 Dec; 92(12):1621-36. PubMed ID: 24989965
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate.
Arnon R; Aharoni R
J Neural Transm (Vienna); 2009 Nov; 116(11):1443-9. PubMed ID: 19669693
[TBL] [Abstract][Full Text] [Related]
4. miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation.
Mandolesi G; De Vito F; Musella A; Gentile A; Bullitta S; Fresegna D; Sepman H; Di Sanza C; Haji N; Mori F; Buttari F; Perlas E; Ciotti MT; Hornstein E; Bozzoni I; Presutti C; Centonze D
J Neurosci; 2017 Jan; 37(3):546-561. PubMed ID: 28100738
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
Aharoni R
J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
[TBL] [Abstract][Full Text] [Related]
6. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
Gentile A; Musella A; Bullitta S; Fresegna D; De Vito F; Fantozzi R; Piras E; Gargano F; Borsellino G; Battistini L; Schubart A; Mandolesi G; Centonze D
J Neuroinflammation; 2016 Aug; 13(1):207. PubMed ID: 27566665
[TBL] [Abstract][Full Text] [Related]
7. Transient receptor potential vanilloid 1 channels modulate the synaptic effects of TNF-α and of IL-1β in experimental autoimmune encephalomyelitis.
Musumeci G; Grasselli G; Rossi S; De Chiara V; Musella A; Motta C; Studer V; Bernardi G; Haji N; Sepman H; Fresegna D; Maccarrone M; Mandolesi G; Centonze D
Neurobiol Dis; 2011 Sep; 43(3):669-77. PubMed ID: 21672630
[TBL] [Abstract][Full Text] [Related]
8. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.
Ruffini F; Rossi S; Bergamaschi A; Brambilla E; Finardi A; Motta C; Studer V; Barbieri F; De Chiara V; Hayardeny L; Comi G; Centonze D; Martino G
Mult Scler; 2013 Jul; 19(8):1084-94. PubMed ID: 23232603
[TBL] [Abstract][Full Text] [Related]
9. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
[TBL] [Abstract][Full Text] [Related]
10. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
Jee Y; Liu R; Bai XF; Campagnolo DI; Shi FD; Vollmer TL
Int Immunol; 2006 Apr; 18(4):537-44. PubMed ID: 16481342
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-9 protects from microglia- and TNF-mediated synaptotoxicity in experimental multiple sclerosis.
Guadalupi L; Vanni V; Balletta S; Caioli S; De Vito F; Fresegna D; Sanna K; Nencini M; Donninelli G; Volpe E; Mariani F; Battistini L; Stampanoni Bassi M; Gilio L; Bruno A; Dolcetti E; Buttari F; Mandolesi G; Centonze D; Musella A
J Neuroinflammation; 2024 May; 21(1):128. PubMed ID: 38745307
[TBL] [Abstract][Full Text] [Related]
12. Glatiramer acetate guards against rapid memory decline during relapsing-remitting experimental autoimmune encephalomyelitis.
LoPresti P
Neurochem Res; 2015 Mar; 40(3):473-9. PubMed ID: 25481047
[TBL] [Abstract][Full Text] [Related]
13. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice.
Aharoni R; Eilam R; Domev H; Labunskay G; Sela M; Arnon R
Proc Natl Acad Sci U S A; 2005 Dec; 102(52):19045-50. PubMed ID: 16365293
[TBL] [Abstract][Full Text] [Related]
14. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis.
Aharoni R; Arnon R; Eilam R
J Neurosci; 2005 Sep; 25(36):8217-28. PubMed ID: 16148229
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate.
Aharoni R; Sasson E; Blumenfeld-Katzir T; Eilam R; Sela M; Assaf Y; Arnon R
Exp Neurol; 2013 Feb; 240():130-44. PubMed ID: 23153580
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation.
Herges K; Millward JM; Hentschel N; Infante-Duarte C; Aktas O; Zipp F
PLoS One; 2011; 6(10):e25456. PubMed ID: 22022398
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate (copaxone) modulates platelet activation and inhibits thrombin-induced calcium influx: possible role of copaxone in targeting platelets during autoimmune neuroinflammation.
Starossom SC; Veremeyko T; Dukhinova M; Yung AW; Ponomarev ED
PLoS One; 2014; 9(5):e96256. PubMed ID: 24788965
[TBL] [Abstract][Full Text] [Related]
18. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond.
Aharoni R
Autoimmun Rev; 2013 Mar; 12(5):543-53. PubMed ID: 23051633
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective Effect of Glatiramer Acetate on Neurofilament Light Chain Leakage and Glutamate Excess in an Animal Model of Multiple Sclerosis.
Aharoni R; Eilam R; Lerner S; Shavit-Stein E; Dori A; Chapman J; Arnon R
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948217
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis.
Begum-Haque S; Sharma A; Kasper IR; Foureau DM; Mielcarz DW; Haque A; Kasper LH
J Neuroimmunol; 2008 Nov; 204(1-2):58-65. PubMed ID: 18804287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
